usdaed

So, what happened? Well, there was a massive financial company making a play, but it didn’t choose *our* chipmaker. No, no. The lucky lady-er, company-wasn’t AMD (Advanced Micro Devices, if we want to get formal), but its longtime rival, Intel. Now, if you’re AMD, imagine you’ve been all dressed up for a gala, only to find out your date picked your best friend instead. Ouch. That sting was felt in the stock prices, as AMD lost more than 5% on the day. Meanwhile, the S&P 500 also dropped-but much less dramatically, like someone tripping on their shoelaces instead of face-planting into a pie.

Before the first bell tolled, Best Buy etched its name into the annals of commerce by opening a portal to a realm where its offerings doubled. This new marketplace, a recursive expansion of its e-commerce veins, now harbors not only the familiar specters of technology but also the uncharted territories of third-party wares. A library, one might say, where the shelves no longer merely echo the curator’s taste but the collective whispers of myriad vendors.

Behold the table below, a modest ledger of ambition. It chronicles Vertiv’s full-year guidance for 2025, revealing an intriguing paradox. Sales rise faster than profits, as if the company were a spendthrift nobleman throwing gold coins into a fountain of innovation. The culprit? Tariffs, those bureaucratic gremlins, and a sudden surge in research and development spending-an investment not unlike stashing rubles under your mattress in anticipation of a brighter tomorrow.

It seems President Trump, that distinguished gentleman who occasionally fancies himself a hatmaker, was perusing a document about youth health initiatives. Among its pages lurked a scheme for the Surgeon General to launch an “educational caravan” highlighting the perils of substances that make one’s eyes widen. THC, the particular gremlin in cannabis that induces giggles and midnight snack cravings, featured prominently in this cautionary tale.

Analysts, those solemn soothsayers of spreadsheets, had conjured visions of $1.23 per share on less than $8.4 billion in revenue. Yet lo! Medtronic, with a flourish, produced $1.26 per share and $8.6 billion in sales. A triumph, one imagines, if not for the inconvenient truth that the curtain fell on profit margins thinner than a nobleman’s excuses.

What transpired today was less a reflection of SoundHound AI’s peculiar virtues-or lack thereof-and more an indictment of broader economic anxieties. Retail earnings reports hinted at tariff-induced inflation, sending tremors through the portfolios of those who favor unprofitable yet visionary enterprises. For SoundHound AI, whose valuation rests upon dreams of future revenue rather than current profits, such news is particularly unwelcome. Even after Tuesday’s correction, the stock trades at a princely 41 times trailing sales-a figure so audacious it could only be described as poetic irony.

And WHO is this newfound prophet, this imminent Bull of the Healthcare Temple? None other than William Blair analyst Matt Larew, who threw caution to the wind with a booming endorsement of Thermo’s stock-an OUTPERFORM, baby! A glorified “BUY!” from the man himself. He can’t tell us *how high* he expects it to fly just yet, but for now, the vibes are righteous.